Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer

Mhd Yaser Al-Marrawi, Bikramajit Singh Saroya, Matthew C. Brennan, Zhaohai Yang, Thomas M. Dykes, Wafik S. El-Deiry

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Fingerprint

Dive into the research topics of 'Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences